uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
Show others and affiliations
2012 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 158, no 3, 355-362 p.Article in journal (Refereed) Published
Abstract [en]

Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL.

Place, publisher, year, edition, pages
2012. Vol. 158, no 3, 355-362 p.
Keyword [en]
mantle cell lymphoma, autologous stem cell transplant, high-dose AraC, rituximab, pre-emptive therapy
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-179002DOI: 10.1111/j.1365-2141.2012.09174.xISI: 000306307500008OAI: oai:DiVA.org:uu-179002DiVA: diva2:543261

Correction in British Journal of Haematology, vol 158, issue 6, 2012, pages 815-816.

DOI: 10.1111/bjh.12006

Available from: 2012-08-07 Created: 2012-08-06 Last updated: 2012-10-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Laurell, AnnaSundström, Christer
By organisation
OncologyMolecular and Morphological Pathology
In the same journal
British Journal of Haematology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 204 hits
ReferencesLink to record
Permanent link

Direct link